Supplementary Table S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Ningning Zhang(Tianjin Medical University Cancer Institute and Hospital), Xiaolu Tao(Shanghai Harbour Engineering Design & Research Institute), Ming Luo(Tianjin Medical University Cancer Institute and Hospital), Jie Shen(Nanjing Drum Tower Hospital), Shukui Qin(81th Hospital of PLA), Di Yang(Shanghai Harbour Engineering Design & Research Institute), Yanqiao Zhang(Harbin Medical University), Ruixuan Luo(Shanghai Harbour Engineering Design & Research Institute), Chongyuan Xu(Nanfang Hospital), Jihui Hao(Tianjin Medical University Cancer Institute and Hospital), Guijie Xin(First Bethune Hospital of Jilin University), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Shuwen Zhang(Tianjin Medical University Cancer Institute and Hospital), Aibing Xu(Nantong Tumor Hospital), Yajin Chen(Sun Yat-sen University), Ge Yu(First Bethune Hospital of Jilin University), Yanxia He(Shanghai Harbour Engineering Design & Research Institute), Jun Yao(First Affiliated Hospital of Henan University of Science and Technology), Fei Zheng(Beijing Friendship Hospital), Gang Wang(Capital University), Meijuan Gao(Shanghai Harbour Engineering Design & Research Institute), Shanzhi Gu(Hunan Cancer Hospital), Yabing Guo(Nanfang Hospital), Junqi Niu(Jilin University), Tian Liu(Tianjin Medical University Cancer Institute and Hospital), Nan Cao(Shanghai Harbour Engineering Design & Research Institute)
Cited by 0
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|614
Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma
|Liver International|2019|591